New trends in the design of drugs against Alzheimer's disease.
First described by Alois Alzheimer in 1907, Alzheimer's disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a growing health problem. AD is currently treated by symptomatic drugs, the acetylcholinesterase inhibitors, based on the cholinergic hypothesis (1976). During the past decade, advances in neurobiology have conducted to the identification of new targets. Although some of these innovative approaches tend to delay onset of AD, others are still symptomatic. In this review, we present an overview of the several strategies and new classes of compounds against AD.
Francotte
P
P
Natural and Synthetic Drugs Research Center, Dept of Medicinal Chemistry, University of Liège, Av. de l'Hôpital, 1, B36, 4000 Liège, Belgium. Pierre.Francotte@ulg.ac.be
Graindorge
E
E
Boverie
S
S
de Tullio
P
P
Pirotte
B
B
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000517:prevention & control; D000596:Amino Acids / Q000494:pharmacology / Q000627:therapeutic use; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D004345:Drug Industry; D004358:Drug Therapy / Q000639:trends; D006801:Humans; D018384:Oxidative Stress
D000596:Amino Acids; D016229:Amyloid beta-Peptides; D000893:Anti-Inflammatory Agents; D018678:Cholinergic Agents